Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $160

Benzinga Newsdesk www.benzinga.com Positive 81.8%

Neg 0% Neu 0% Pos 81.8%

Guggenheim analyst Seamus Fernandez maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $130 to $160.